Bubendorf/Basel, August 28, 2015 – Bachem Group (SIX: BANB) increased its sales by about 15% to nearly 100 million CHF in the first half of 2015 (H1 2014: 86.7 million CHF). Group sales in local currency (LC) for the first half were higher than in any other half-year period since the company’s founding. Generics sales rose by approx. 9% in LC to 49.3 million CHF and sales of research ingredients were also very strong in both the catalog products and custom synthesis business. Bachem achieved further stellar growth in the New Chemical Entities (NCEs) business, where sales rose by more than 22% in LC. Despite negative currency effects, EBITDA advanced to 26.8 million CHF and EBIT to 17.6 million CHF. Excluding last year’s extraordinary gain of 2.0 million CHF on the divestment of the immunology product line, EBIT for the period was up by about 22%. Net income rose to 12.6 million CHF. In view of the pleasing first-half results, the orders on hand and current market developments, 2015 is expected to be a very good year.